ClinicalTrials.gg
CompletedNCT00275821EXCITEUpdated Mar 16, 2011Results posted

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of Ranibizumab 0.3 mg - 3 times monthly, then quarterly and Ranibizumab 0.5 mg - 3 times monthly, then quarterly in Age Related Macular Degeneration, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-03-16.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
23rd of 124
353 · median 64
Started
2005
with 4 others
Phase 3
31 of 125
2 open now
Registered
7th of 125
by date
Lead sponsor
7 of 125
Novartis

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 23rd largest by enrollment of the 124 interventional ones that give a count, is one of 5 that started in 2005, is one of 31 in phase 3, and was the 7th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.

03

Conditions studied

  • Age Related Macular Degeneration

Keywords

  • Age-related macular degeneration, ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component
  • Patients who have a BCVA score between 73 and 24 letters, inclusively, in the study eye using ETDRS-like grading charts (approximately 20/40 to 20/320)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.
  • History of submacular surgery or other surgical intervention for AMD in the study eye, glaucoma filtration surgery, corneal transplant surgery.
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline.

Other protocol-defined inclusion/exclusion criteria applied to the study.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.3 mg - 3 times monthly, then quarterly

    Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly

  • Experimental
    Ranibizumab 0.5 mg - 3 times monthly, then quarterly

    Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly

  • Active comparator
    Ranibizumab 0.3 mg monthly

    Drug: Ranibizumab 0.3 mg monthly

Interventions

  • Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.

  • Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.

  • Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12

    Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12

    Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

    Time frame: Baseline to Month 12

  2. Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12

    Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.

    Time frame: Baseline to Month 12

  3. Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12

    Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.

    Time frame: Baseline to Month 12

07

Results

Posted Mar 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Started120118115
Completed10695103
Not completed142312
Withdrew: Adverse event4125
Withdrew: Administrative problems344
Withdrew: Withdrawal by subject021
Withdrew: Lost to follow-up011
Withdrew: Death021
Withdrew: Lack of efficacy210
Withdrew: Protocol violation510

Outcome measures

PrimaryMean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12

Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.

Time frame:
Baseline to Month 12
Reported as:
Mean · letters
Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12
lettersRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 124.9 ± 13.133.8 ± 13.338.3 ± 11.31
SecondaryMean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12

Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Time frame:
Baseline to Month 12
Reported as:
Mean · mm^2
Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12
mm^2Ranibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12-0.21 ± 5.616-1.51 ± 4.802-1.28 ± 4.367
SecondaryMean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12

Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.

Time frame:
Baseline to Month 12
Reported as:
Mean · micrometers
Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12
micrometersRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12-96.0 ± 96.82-105.6 ± 128.98-105.3 ± 128.55
SecondaryMean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12

Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.

Time frame:
Baseline to Month 12
Reported as:
Mean · Micrometers
Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12
MicrometersRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12-93.3 ± 100.88-97.5 ± 117.52-97.9 ± 112.47

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly—15/120 (12.5%)66/120 (55%)
Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly—23/118 (19.5%)71/118 (60.2%)
Ranibizumab 0.3 mg Monthly—20/115 (17.4%)64/115 (55.7%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Cardiac failureCardiac disorders3/1200/1181/115
Atrial fibrillationCardiac disorders0/1202/1182/115
PneumoniaInfections and infestations1/1200/1182/115
Atrial flutterCardiac disorders0/1202/1180/115
Retinal pigment epithelial tear (Study eye)Eye disorders0/1202/1180/115
AnaemiaBlood and lymphatic system disorders0/1200/1181/115
Angina pectorisCardiac disorders0/1200/1181/115
Myocardial infarctionCardiac disorders1/1200/1181/115
Ventricular tachycardiaCardiac disorders0/1200/1181/115
DysphagiaGastrointestinal disorders0/1200/1181/115
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRanibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg Monthly
Eye pain (Study eye)Eye disorders22/12014/11824/115
Conjunctival haemorrhage (Study eye)Eye disorders23/12019/11812/115
Visual acuity reduced (Study eye)Eye disorders15/12019/1189/115
Intraocular pressure increased (Study eye)Investigations6/1207/11817/115
NasopharyngitisInfections and infestations11/1204/1188/115
Ocular hyperaemia (Study eye)Eye disorders8/12010/1187/115
HypertensionVascular disorders10/1206/1188/115
Vitreous floaters (Study eye)Eye disorders6/1206/1188/115
Retinal haemorrhage (Study eye)Eye disorders4/1208/1182/115
ArthralgiaMusculoskeletal and connective tissue disorders1/1203/1187/115

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ranibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg MonthlyTotal
50 - < 6513121035
65 - < 75372845110
75 - < 85617246179
≥ 85961429
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.3 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.5 mg - 3 Times Monthly, Then QuarterlyRanibizumab 0.3 mg MonthlyTotal
Female707366209
Male504549144
08

Study locations

1 site
  • Novartis
    Basel, 4002, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2006
First posted
Jan 12, 2006
Start
Dec 2005
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Mar 16, 2011
Last update
Mar 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00275821
Lead sponsor
Novartis
First posted
Jan 12, 2006
Start date
Dec 2005
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Mar 16, 2011
Last update
Mar 16, 2011

Study contacts

Novartis
study chair · Novartis - Including Sites in Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion